WELCOME TO The HEALTHCARE REPORT
Newsletter | Member Login | Signup
Home > Companies > MEDNAX
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Health Technology
Bearpac Medical, LLC | March 16, 2022
Bearpac Medical, LLC announced that Vizient, Inc., the nation's leading member-driven healthcare performance improvement organization, has awarded Bearpac Medical, LLC an Innovative Technology contract for their Passio Pump Drainage System. The contract was awarded based on hospital experts serving on one of Vizient's member-led councils recommending the Passio Pump Drainage System. It demonstrates to Vizient members that the Passio Pump Drainage System possesses unique characteristic...
EHRIntelligence | February 10, 2020
Despite advances in health information technology, interoperability in the healthcare world is an area that needs to improve to benefit the providers and especially patient wellness. In a recent ONC data brief, researchers analyzed data from the National EHR Surveys from 2015 to 2017 and came to the conclusion that interoperability has been somewhat stagnant over the two year time period. In fact, only about 10 percent of physicians were able to send, receive, and integrate health data into thei...
Digital Healthcare
AdhereHealth | December 18, 2021
AdhereHealth, a healthcare technology leader in medication adherence insights and health outcomes, has entered into a strategic partnership with Hero, the market leader in digital in-home care. This new agreement enables AdhereHealth to deploy Hero's digital in-home care platform to help high-risk, high-cost, chronically ill patients adhere to complex medication regimens. Hero's platform includes a connected smart pill dispenser, which automatically sorts and dispenses medic...
Future of Healthcare
Medicago | May 06, 2022
Medicago announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine recombinant, adjuvanted, in the New England Journal of Medicine. The Phase 3 trial studied the two-dose regimen of COVIFENZ® given 21 days apart versus placebo in over 24,000 subjects aged 18 and above. Common side effects in the vaccine group included injection site pain, headache, fatigue, fever, muscle aches, and chills. COVIFENZ® is indicated for active immunizatio...
Health Technology, AI
Article
Medical Devices
Whitepaper
Digital Healthcare, Medical Devices
infographic
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE